Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.

Abstract excerpt

For patients with chronic myelogenous leukemia who fail first-line therapy, several factors should be considered for the decision of the next treatment option. Second-generation tyrosine kinase inhibitors (TKIs) dasatinib, nilotinib, and bosutinib offer improved potency and a high likelihood of success for these patients. Overall, efficacy data are comparable for these agents, and so physicians should consider...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aniline Compounds
• Share to Dasatinib
• Share to Drug Monitoring